An observational study in Acute Pancreatitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Assiut University · Observational
Among 12 studies in Pancreatitis by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis · Assiut University.
Among the 12 studies in Pancreatitis by Assiut University, this one is the 3rd largest by planned enrollment of the 11 observational ones, is one of 2 that started in 2026, is one of 7 observational ones, and was the 11th registered.
557 studies on the registry are indexed under Pancreatitis; 164 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 192 observational studies indexed under Pancreatitis.
Browse Pancreatitis studies →6 of the 12 studies in Pancreatitis by Assiut University are open now, in 1 country. Each count lists the studies.
Of the 111 Pancreatitis studies recruiting now, 61 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2026.
Median enrollment 90 across the 1 interventional studies, 100 across the 11 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
4 of the studies in Pancreatitis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233551Assiut UniversityUtilization of CBC-Derived Inflammatory Indices in Assessing Severity and Prognosis of Acute Pancreatitis. | 2026-11-30 |
| NCT06653205Assiut UniversityPrediction of Acute Pancreatitis Outcome | 2026-12 |
| NCT07793734Assiut UniversityCBC-Derived Inflammatory Indices in Acute Pancreatitis | 2027-08-26 |
| NCT07753980Assiut UniversityPresentations and Outcomes of Acute Pancreatitis | 2027-09 |
Among the 12 studies in Pancreatitis by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
Evaluate the outcomes of the patients and their possible predictors.
Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas characterized by variable involvement of regional tissues and distant organ systems. The disease may range from mild interstitial edema to severe pancreatic necrosis associated with multiple organ failure and high mortality rates [1,2]. Acute pancreatitis is considered one of the leading gastrointestinal causes of hospital admission worldwide and its incidence has progressively increased over recent decades [3]. The pathogenesis of acute pancreatitis is mainly related to premature activation of pancreatic digestive enzymes within pancreatic acinar cells, resulting in autodigestion of pancreatic tissue and activation of inflammatory pathways [1]. This inflammatory response may progress to systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS), renal failure, shock, and multiorgan dysfunction syndrome (MODS) in severe cases[ 2,4]. Although approximately 80% of patients experience mild self-limited disease with favorable outcomes, nearly 20% develop severe acute pancreatitis associated with pancreatic necrosis, infected collections, persistent organ failure, and systemic complications [3,8]. The overall mortality rate of acute pancreatitis ranges from 3% to 10%, while mortality in severe acute pancreatitis may reach 20-30%, particularly in patients with infected pancreatic necrosis and persistent organ failure4 and [8].Early identification of severe disease and accurate assessment of prognosis are therefore essential to improve patient outcomes and reduce morbidity and mortality [7,8]. In Upper Egypt, particularly at Al-Rajhi University Hospital, prospective data regarding the clinical presentation, etiological factors, disease severity, complications, and outcomes of patients admitted with acute pancreatitis remain limited. In addition, the association between demographic characteristics, comorbidities, severity scores, and short-term clinical outcomes has not been adequately evaluated in the local population.
Accordingly, this prospective study aims to describe the clinical characteristics of hospitalized patients with acute pancreatitis, identify factors associated with adverse outcomes, and evaluate the prognostic value of the Ranson and APACHE II scoring systems. The findings may contribute to improved early risk stratification, support clinical decision-making, optimize resource utilization, and ultimately enhance patient care at Al-Rajhi University Hospital.
All enrolled patients will undergo:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
arterial blood gases
Frequency and types of clinical patterns of acute pancreatitis and the fates of patients.
Time frame: july 2026-july 2027
No study locations are listed for this record.
Plan to share: Undecided
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.